Regulatory Barriers to Research on Cannabis and Cannabinoids: A Proposed Path Forward.
作者信息
Piomelli Daniele, Solomon Robert, Abrams Donald, Balla Agnes, Grant Igor, Marcotte Thomas, Yoder John
机构信息
Department of Anatomy and Neurobiology, Center for the Study of Cannabis, University of California, Irvine, School of Medicine, Irvine, California.
Economic Development Clinic, Center for the Study of Cannabis, University of California, Irvine, School of Law, Irvine, California.
出版信息
Cannabis Cannabinoid Res. 2019 Mar;4(1):21-32. doi: 10.1089/can.2019.0010.
Abstract
摘要
相似文献
1
Regulatory Barriers to Research on Cannabis and Cannabinoids: A Proposed Path Forward.大麻及大麻素研究的监管障碍：一条前进的建议路径。
Cannabis Cannabinoid Res. 2019 Mar;4(1):21-32. doi: 10.1089/can.2019.0010.
2
Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence.大麻、大麻素与大脑形态：证据回顾。
Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jun;6(6):627-635. doi: 10.1016/j.bpsc.2020.07.009. Epub 2020 Jul 21.
3
Cannabis and cannabinoids: pharmacology and therapeutic potential.大麻及大麻素：药理学与治疗潜力。
Neurol Neurochir Pol. 2022;56(1):4-13. doi: 10.5603/PJNNS.a2022.0015. Epub 2022 Feb 8.
4
The National Cancer Institute and Cannabis and Cannabinoids Research.美国国家癌症研究所与大麻及大麻素研究
J Natl Cancer Inst Monogr. 2021 Nov 28;2021(58):35-38. doi: 10.1093/jncimonographs/lgab014.
5
Cannabis and cannabinoids: pharmacology and rationale for clinical use.大麻与大麻素：药理学及临床应用原理
Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. doi: 10.1159/000057150.
6
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.大麻素治疗多发性硬化症症状：证据现状。
Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x.
7
Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.大麻和大麻素药物研发：评估植物源与单分子方法。
Int Rev Psychiatry. 2018 Jun;30(3):277-284. doi: 10.1080/09540261.2018.1474730.
8
Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds.向以色列毒物信息中心报告的大麻和合成大麻素暴露情况：研究医疗和娱乐性化合物暴露的差异。
Int J Drug Policy. 2020 Mar;77:102711. doi: 10.1016/j.drugpo.2020.102711. Epub 2020 Feb 29.
9
Cannabinoids: for better and for worse
.大麻素：有好有坏。
Dialogues Clin Neurosci. 2020 Sep;22(3):201-204. doi: 10.31887/DCNS.2020.22.3/fthibaut.
10
Therapeutic potential of cannabinoids in combination cancer therapy.大麻素联合癌症疗法的治疗潜力。
Adv Biol Regul. 2021 Jan;79:100774. doi: 10.1016/j.jbior.2020.100774. Epub 2021 Jan 6.
引用本文的文献
1
Targeting Gastrointestinal Cancers with Cannabidiol: Mechanisms, Challenges, and Therapeutic Implications.用大麻二酚靶向治疗胃肠道癌症：作用机制、挑战及治疗意义
Med Oncol. 2025 Jun 3;42(7):237. doi: 10.1007/s12032-025-02790-6.
2
Associations between cannabis use and same-day health and substance use behaviors.大麻使用与当日健康及物质使用行为之间的关联。
Addict Behav. 2025 Apr;163:108239. doi: 10.1016/j.addbeh.2024.108239. Epub 2024 Dec 31.
3
Cannabis use in a Canadian long-term care facility: a case study.加拿大长期护理机构中的大麻使用情况：一项案例研究。
BMC Geriatr. 2024 May 29;24(1):467. doi: 10.1186/s12877-024-05074-2.
4
The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder.药用大麻作为阿片类物质使用障碍新兴疗法的作用。
Pain Ther. 2024 Jun;13(3):435-455. doi: 10.1007/s40122-024-00599-1. Epub 2024 Apr 27.
5
How and why adults use cannabis during physical activity.成年人在体育活动期间使用大麻的方式及原因。
J Cannabis Res. 2022 May 18;4(1):24. doi: 10.1186/s42238-022-00134-z.
6
Between Science and Big Business: Tapping Mary Jane's Uncharted Potential.在科学与大企业之间：挖掘大麻的未知潜力。
ACS Cent Sci. 2022 Feb 23;8(2):156-168. doi: 10.1021/acscentsci.1c01100. Epub 2022 Jan 26.
本文引用的文献
1
Compromised External Validity: Federally Produced Cannabis Does Not Reflect Legal Markets.外部有效性受损：联邦生产的大麻无法反映合法市场。
Sci Rep. 2017 Apr 19;7:46528. doi: 10.1038/srep46528.
2
Molecular Pharmacology of Phytocannabinoids.植物大麻素的分子药理学
Prog Chem Org Nat Prod. 2017;103:61-101. doi: 10.1007/978-3-319-45541-9_3.
3
Phytochemistry of Cannabis sativa L.大麻的植物化学
Prog Chem Org Nat Prod. 2017;103:1-36. doi: 10.1007/978-3-319-45541-9_1.
4
Cannabidiol Claims and Misconceptions.大麻二酚的说法和误解。
Trends Pharmacol Sci. 2017 Mar;38(3):198-201. doi: 10.1016/j.tips.2016.12.004. Epub 2017 Jan 12.
5
6
Federal barriers to Cannabis research.联邦政府对大麻研究的限制。
Science. 2016 Jun 3;352(6290):1182. doi: 10.1126/science.aaf7450. Epub 2016 Jun 2.
7
Effects of Schedule I drug laws on neuroscience research and treatment innovation.附表 I 类药物法律对神经科学研究和治疗创新的影响。
Nat Rev Neurosci. 2013 Aug;14(8):577-85. doi: 10.1038/nrn3530. Epub 2013 Jun 12.
8
A second endogenous cannabinoid that modulates long-term potentiation.第二种调节长时程增强的内源性大麻素。
Nature. 1997 Aug 21;388(6644):773-8. doi: 10.1038/42015.
9
SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.SR141716A，一种强效且选择性的脑大麻素受体拮抗剂。
FEBS Lett. 1994 Aug 22;350(2-3):240-4. doi: 10.1016/0014-5793(94)00773-x.
10
Formation and inactivation of endogenous cannabinoid anandamide in central neurons.中枢神经元内源性大麻素花生四烯乙醇胺的形成与失活。
Nature. 1994 Dec 15;372(6507):686-91. doi: 10.1038/372686a0.
Zotero 插件